Saba Khan¹*, Jaya Agnihotri², Alina Bi Shaikh³, Mahnaz Sayyed³, Masnoon Khan³ and Arif Khan³

¹HKCP, Masters Research Student, Department of Pharmaceutics, Mumbai, Maharashtra, India
²HKCP, Associate Professor, Department of Pharmaceutics, Mumbai, Maharashtra, India
³HKCP, Final Year Student, Mumbai, Maharashtra, India

*Corresponding Author: Saba Khan, HKCP, Masters Research Student, Pharmaceutics, Mumbai, Maharashtra, India.

Received: September 14, 2023; Published: December 06, 2023

Abstract

Scientists dedicated their efforts to enhancing drug delivery methods while preserving the integrity of these methods' undesirable traits. This dedication ultimately resulted in the creation of proniosomes, a revolutionary medication delivery system. Due to their unique benefits, proniosomes stand out from niosomes and liposomes. These proniosomes are made of non-ionic, water-soluble dry formulations that are added to a carrier system. Upon hydration, these proniosomes transform into niosomes, effectively addressing the instability issues associated with traditional delivery systems. Niosomes, in turn, exhibit tremendous potential for improving the dissolution, accessibility, and absorption of a wide range of medications, whether they are hydrophilic or hydrophobic. Additionally, proniosomes offer a versatile approach to drug delivery, enabling precise medication delivery to the desired target site. The risk of unwanted side effects is reduced by this regulated release technique. Recognizing and understanding the limitations of each study is imperative since each research approach possesses its unique set of advantages and drawbacks. Observational studies can employ a variety of design methodologies, including ecological, prospective, retrospective, case-control, case-crossover, or cross-sectional cohort designs. In the realm of diagnostic research, a critical subset of observational experiments is dedicated to comparing the accuracy of different diagnostic methods and tests against established diagnostic benchmarks. It is essential to underscore that biomedical research heavily relies on data collected through rigorously validated scientific methodologies and employs appropriate statistical methods to derive meaningful insights. Consequently, selecting a robust study strategy is paramount in ensuring an objective and impartial evaluation of research inquiries. This comprehensive review encompasses a wide array of facets related to proniosomes, encompassing their advantages, preparation techniques, mechanisms of action, materials and specifications, study designs, as well as characterization and evaluation parameters.

Keywords: Proniosomes; Carrier; Transdermal; Skin Permeation; Application

References

1. Radha G., et al. “A review on proniosomal drug delivery system for targeted drug action”. Journal of Basic and Clinical Pharmacy2 (2013): 42.
2. Arunothayanun P., et al. “The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether”. International Journal of Pharmaceutics1 (2000): 7-14.
3. Mittal S., et al. “Proniosomes: The effective and efficient drug-carrier system”. Therapeutic Delivery2 (2020): 125-137.
4. Paolino D., et al. “Improved in vitro and in vivo collagen biosynthesis by asiaticoside-loaded ultradeformable vesicles”. Journal of Controlled Release1 (2012): 143-151.
5. Paolino D., et al. “Paclitaxel-loaded ethosomes®: Potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses”. European Journal of Pharmaceutics and Biopharmaceutics 81.1 (2012): 102-112.
6. Cserháti T. “Alkyl ethoxylated and alkylphenol ethoxylated nonionic surfactants: Interaction with bioactive compounds and biological effects”. Environmental Health Perspectives4 (1995): 358-364.
7. Hofland HEJ., et al. “Interactions of non-ionic surfactant vesicles with cultured keratinocytes and human skin in vitro: A survey of toxicological aspects and ultrastructural changes in stratum corneum”. Journal of Controlled Release1-2 (1991): 155-167.
8. Fang JY., et al. “In vitro skin permeation of estradiol from various proniosome formulations”. International Journal of Pharmaceutics1-2 (2001): 91-99.
9. Gupta A., et al. “Design and development of a proniosomal transdermal drug delivery system for captopril”. Tropical Journal of Pharmaceutical Research, 6.2 (2007).
10. Kaur Prabhjot and Kaur Loveleenpreet. “Niosomes Used as Targeting Drug Delivery System: A Overview”. Asian Journal of Research in Chemistry 7 (2014): 687-692.
11. McCrudden M T., et al. “Strategies for enhanced peptide and protein delivery”. Therapeutic Delivery 4.5 (2013): 593-614.
12. Muzzalupo R and Tavano L. “Niosomal drug delivery for transdermal targeting: Recent advances”. Research and Reports in Transdermal Drug Delivery 23 (2015).
13. Khatoon M., et al. “Proniosomes derived niosomes: Recent advancements in drug delivery and targeting”. Drug Delivery 24.2 (2017): 56-69.
14. Ammar H O., et al. “Proniosomes as a carrier system for transdermal delivery of tenoxicam”. International Journal of Pharmaceutics 405.1-2 (2011): 142-152.
15. Akhilesh D., et al. “Proniosomes - A propitious provesicular drug carrier”. International Journal of Pharmaceutical Sciences and Research 1 (2011): 98-103.
16. Kumar K and Rai AK. “Development and evaluation of proniosomes as a promising drug carrier to improve transdermal drug delivery”. IRJP 2 (2011): 71-74.
17. ND Shukla and M Tiwari. “Proniosomal Drug Delivery System- Clinical Applications”. International Journal of Research in Pharmaceutical and Biomedical Sciences 3 (2011): 880-887.
18. AK Jha., et al. “Vesicular System -Carrier for Drug Delivery”. Der Pharmacia Sinica4 (2011): 192-202.
19. Sagar G H., et al. “Self-assembled surfactant nano-structures important in drug delivery: a review” (2007).
20. Walve J R., et al. “Transfersomes: a surrogated carrier for transdermal drug delivery system” (2011).
21. Sudarshan Upadhye S and Rafik IN. “Proniosomes: A novel vesicular drug delivery system”. American Journal of PharmTech Research 10.2 (2020): 260-273.
22. Comelles F., et al. “Influence of ionic surfactants on the formation of liquid crystals in oleic acid/glycol/water systems”. Journal of Surfactants and Detergents 10.3 (2007): 137-144.
23. Murdan S. “Interaction of a nonionic surfactant-based organogel with aqueous media”. International Journal of Pharmaceutics 180.2 (1999): 211-214.
24. Wu X and Guy R H. “Applications of nanoparticles in topical drug delivery and cosmetics”. Journal of Drug Delivery Science and Technology 19.6 (2009): 371-384.
25. Chen S., et al. “Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications”. European Journal of Pharmaceutics and Biopharmaceutics 144 (2019): 18-39.
26. Cerqueira-Coutinho C., et al. “Niosomes as nano-delivery systems in the pharmaceutical field”. Critical Reviews^TM in Therapeutic Drug Carrier Systems 33.2 (2016): 195-212.
27. Abu Hajleh MN., et al. “The revolution of cosmeceuticals delivery by using nanotechnology: A narrative review of advantages and side effects”. Journal of Cosmetic Dermatology 12 (2021): 3818-3828.
28. Biju S., et al. “Vesicular systems: an overview”. Indian Journal of Pharmaceutical Sciences2 (2006).
29. Kandpal N., et al. “Proniosomes: A pro vesicular system in ocular drug delivery”. Journal of Advanced Biotechnology and Experimental Therapeutics 6.3 (2023): 622.
30. Chandra A and Sharma P K. “Proniosome-based drug delivery system of piroxicam”. African Journal of Pharmacy and Pharmacology 2.9 (2008): 184-190.
31. Akhilesh D., et al. “Comparative study of carriers used in proniosomes”. International Journal of Pharmaceutical and Chemical Sciences 3 (2012): 6-12.
32. Sudhamani T., et al. “Proniosomes—a promising drug carriers”. International Journal of PharmTech Research 2 (2010): 1446-1454.
33. Kakar R., et al. “Proniosomes: An emerging vesicular system in drug delivery and cosmetics”. Der Pharmacia Lettre 4 (2010): 227-239.
34. Sankar V., et al. “Proniosomes as drug carriers”. Pakistan Journal of Pharmaceutical Sciences 23.1 (2010): 103-107.
35. Vora B., et al. “Proniosome-based transdermal delivery of levonorgestrel for effective contraception”. Journal of Controlled Release 54.2 (1998): 149-165.
36. Kumar K and Rai A. “Development and evaluation of proniosome- encapsulated curcumin for transdermal administration”. Tropical Journal of Pharmaceutical Research 10.6 (2011).
37. N Politis., et al. “Design of experiments (DoE) in pharmaceutical development”. Drug Development and Industrial Pharmacy 43.6 (2017): 889-901.
38. Friston K J., et al. “The trouble with cognitive subtraction”. NeuroImage 4.2 (1996) 97-104.
39. Solanki A B., et al. “Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design”. AAPS PharmSciTech 8.4 (2007).
40. Amaro E., et al. “Study design in fMRI: Basic principles”. Brain and Cognition 60.3 (2006): 220-232.
41. Mujoriya RZ and Bodla R. “Niosomthe the -challenge in preparation for pharmaceutical scientist”. International Journal of Applied Pharmaceutics 3 (2011): 11-15.
42. Noordzij M., et al. “Study designs in clinical research”. Nephron Clinical Practice 113.3 (2009): c218-c221.
43. Biberstein M and Parker B A. “Enema-induced hyperphosphatemia”. The American Journal of Medicine 79.5 (1985): 645-646.
44. Bello A K., et al. “Population-based screening for microalbuminuria among relatives of CKD patients: The Kidney Evaluation and Awareness Program in Sheffield (KEAPS)”. American Journal of Kidney Diseases 52.3 (2008): 434-443.
45. Ibeiez L., et al. “Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease”. Kidney International 67.6 (2012): 2393-2398.
46. D’Arcy P. “Handbook of pharmaceutical excipients”. 2^nd edn Ainley Wade and Paul J. Weller (Eds Joint publication of the american pharmaceutical association and the royal pharmaceutical society of great Britain, The Pharmaceutical Press, London, 1994. ISBN: 0 85369 305 6 (UK); 0 91730 66 8 (USA). Price £140; 672 pages. International Journal of Pharmaceutics 123.2 (1995): 301-302.
47. Radha G., et al. “A review on proniosomal drug delivery system for targeted drug action”. Journal of Basic and Clinical Pharmacy 4.2 (2013): 42.
48. Nasr M. “In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration”. AAPS PharmSciTech 11.1 (2010): 85-89.
49. Abd-Elbary A., et al. “Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium”. International Journal of Pharmaceutics 357.1-2 (2008): 189-198.
50. Maya W and Ashar S. “Proniosomal drug delivery systems: An overview”. International Journal of Pharmaceutical and Chemical Sciences 1.3 (2012): 1044-1056.
51. Parthibarajan R., et al. “Formulation and evaluation of methotrexate proniosomal powder”. International Journal of Pharmacy and Pharmaceutical Sciences 4.11 (2012): 175-178.
52. Yadav K., et al. “Proniosomal Gel: A provesicular approach for transdermal drug delivery”. Der Pharmacia Lettre 2.4 (2010): 189-198.
53. Goudanavar P and Joshi VG. “An engineered specificity of Irinotecan loaded Proniosomes: Design and Characterization”. International Journal of Drug Delivery3 (2011): 472.
54. FShi B., et al. “Stealth PEG-PHDCA niosomes: Effects of Chain Length of PEG and Particle Size on Niosomes Surface Properties, In Vitro Drug Release, Phagocytic Uptake, In Vivo Pharmacokinetics and Antitumor Activity”. Journal of Pharmaceutical Sciences 95.9 (2006): 1873-1887.
55. Pawar H., et al. “Novel vesicular drug delivery system for topical delivery of indomethacin”. Drug Delivery Letters 5.1 (2015): 40-51.

Citation

Citation: Jaya Shree., et al. “A Review of Cyclodextrin-Based Nanosponges as Novel Drug Delivery System".Acta Scientific Pharmaceutical Sciences 8.1 (2024): 11-19.

Copyright

Copyright: © 2024 Jaya Shree., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.